Unknown

Dataset Information

0

Risk Factors and Outcomes of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy.


ABSTRACT: We identified clinical characteristics and risk factors of choroidal neovascularization (CNV) in eyes with prior episode of central serous chorioretinopathy (CSC). This retrospective case-control study included those initially diagnosed with CSC and developed CNV secondarily (Group 1, n?=?16), those diagnosed with CNV in eyes of previous putative CSC (Group 2, n?=?14), and those initially diagnosed with CSC, and did not develop CNV secondarily, as a control group for Group 1 (Group 3, n?=?250). Clinical characteristics including treatment outcomes were assessed. Demographics and multimodal imaging at the time of CSC diagnosis of secondary CNV were compared between the groups to identify risk factors. Duration from diagnosis of CSC to development of CNV in Group 1 was 40.2?±?42.0 months. Classic CNV was noted in 23 (76.7%) eyes. After treatment with intravitreal antiangiogenics with average of 4.9 times, visual acuity improved in Group 1 and Group 2 (p?=?0.002). Multivariate analysis revealed that systemic hypertension, pigmentary changes, and double layer sign were associated with development of CNV secondary to CSC (p?

SUBMITTER: Lee GI 

PROVIDER: S-EPMC6408555 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Risk Factors and Outcomes of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy.

Lee Ga-In GI   Kim A Young AY   Kang Se Woong SW   Cho Soo Chang SC   Park Kyu Hyung KH   Kim Sang Jin SJ   Kim Kyung Tae KT  

Scientific reports 20190308 1


We identified clinical characteristics and risk factors of choroidal neovascularization (CNV) in eyes with prior episode of central serous chorioretinopathy (CSC). This retrospective case-control study included those initially diagnosed with CSC and developed CNV secondarily (Group 1, n = 16), those diagnosed with CNV in eyes of previous putative CSC (Group 2, n = 14), and those initially diagnosed with CSC, and did not develop CNV secondarily, as a control group for Group 1 (Group 3, n = 250).  ...[more]

Similar Datasets

| S-EPMC4816359 | biostudies-other
| S-EPMC5226680 | biostudies-other
| S-EPMC8288056 | biostudies-literature
| S-EPMC7987178 | biostudies-literature
| S-EPMC4816351 | biostudies-other
| S-EPMC7447124 | biostudies-literature